Day: November 10, 2022

Completes first two commercial customer installations for Acuitas AMR Gene Panel OpGen subsidiary, Curetis, signed collaboration agreement with BioVersys AG and R&D collaboration agreement with FIND for the Unyvero A30 RQ platform Elects Yvonne Schlaeppi as new, independent non-executive director to the board Management conference call scheduled for November 10, 2022, at 4:30 p.m. ESTROCKVILLE, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its third quarter 2022 financial and operating results. Management will host an investor call to discuss quarterly results and provide a business update. Oliver Schacht, President & CEO of OpGen, commented,...

MINNEAPOLIS, Nov. 10, 2022 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA) , a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended September 30, 2022. Management is hosting an earnings conference call today at 4:30 p.m. ET. The third quarter was marked by meaningful progress. Q3 and early Q4 Highlights:First Patient Enrolled in the company’s Aspire Trial, Panbela’s clinical trial in the first-line treatment of metastatic pancreatic cancer. Announced Regulatory approval for the opening of Aspire Trial sites in Spain, France and Italy. Received approval from the Australian Human Research Ethics Committee (HREC) to expand the Aspire Trial to Australia. Poster presentation...

– Significant Gross Margin Expansion and Record Quarterly Operating Cash Flow – CHINO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) — Karat Packaging Inc. (Nasdaq: KRT) (“Karat”), a specialty distributor and manufacturer of environmentally friendly, disposable foodservice products and related items, today announced financial results for its third quarter and nine-months ended September 30, 2022. Third Quarter 2022 HighlightsNet sales of $110.0 million, up 7.1 percent from the prior-year quarter. Gross profit of $34.2 million, up 14.7 percent from the prior-year quarter. Gross margin of 31.1 percent, increased from 29.0 percent from the prior-year quarter. Net income of $6.2 million, up 51.1 percent from the prior-year quarter. Net income margin of 5.6 percent, increased from 4.0 percent from the prior-year quarter. Adjusted EBITDA...

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases (“CNS”), today reported financial results and recent corporate highlights for the third quarter ended September 30, 2022. “I am pleased that Avenue has achieved important financial milestones providing a path to continue developing drugs for central nervous system disorders. We recently had a collaborative meeting with the U.S. Food and Drug Administration (“FDA”) laying the foundation for conducting a study that could support NDA resubmission for IV Tramadol, and we also completed the acquisition of Baergic Bio, which added a novel clinical-stage anxiolytic and antiepileptic...

Solid Progress Towards Long-Term Goals IRVING, Texas, Nov. 10, 2022 (GLOBE NEWSWIRE) — AgileThought, Inc. (“AgileThought” or the “Company”) (NASDAQ: AGIL), a global provider of digital transformation services, custom software development, and next generation technologies, today reported results for the third quarter ended September 30, 2022. Third Quarter 2022 Highlights and Results:Revenue increased 7.4% year-over-year to $43.4 million from $40.4 million in Q3 2021, but decreased 6.0% sequentially from $46.2 million in Q2 2022, as the Company continues its exit from non-core business. Gross margin of 34.3% increased 770 bps year-over-year from 26.6% in Q3 2021, and increased 100 bps sequentially from 33.3% in Q2 2022. 6 new clients added during the quarter.“I am very proud of our third quarter achievements, with revenue above...

– On Track for Updates on pheEDIT and juMPStart Programs by Year-End – – Strong Financial Position with Cash Runway into Fourth Quarter 2024 – – Promoted Albert Seymour, Ph.D., to Chief Executive Officer Driving Clinical Trials and Genetic Medicines Platform Forward for Patients – BEDFORD, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) — Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the third quarter ended September 30, 2022, and highlighted recent accomplishments. “We remain on track to provide an update from our pheEDIT and juMPStart clinical trials, including site initiations and enrollment status, by the end of this year,” said Albert Seymour, Ph.D., President and Chief Executive Officer of Homology Medicines. “With our recent pipeline...

Cash, cash equivalents and investments of $262.1 million as of September 30, 2022; cash runway expected to fund operations into mid-2024SAN FRANCISCO and SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) — Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced financial results for the quarter ended September 30, 2022, and recent corporate updates. “We continue to make advances with our proprietary programs, and are encouraged by what we’re seeing thus far in the ongoing dose escalation for KIN-2787 monotherapy, our pan-RAF inhibitor,” said Nima Farzan, chief executive officer, Kinnate Biopharma Inc. “We are actively investigating multiple targets as part of the Kinnate Discovery Engine and look forward to having a third program enter the clinic next year. We remain well funded...

RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2022 (GLOBE NEWSWIRE) — Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced its operating and financial results for the third quarter 2022. Recent HighlightsOver 1,900 procedures were performed globally during the nine months ended September 30, 2022, representing growth of 27% over the prior year Five new Senhance program initiations year to date, 3 in Germany, 1 in Japan, 1 in CIS region Submitted FDA 510(k) application for pediatric indication in the U.S. Received the Society of Laparoscopic & Robotic Surgeons 2022 Innovation of the Year award for the Intelligent Surgical Unit™(ISU™) The Company had cash,...